Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

61.15
+1.332.22%
Volume:1.26M
Turnover:76.12M
Market Cap:4.48B
PE:-36.50
High:61.99
Open:59.77
Low:59.47
Close:59.82
52wk High:62.32
52wk Low:14.79
Shares:73.27M
Float Shares:61.73M
Volume Ratio:1.73
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6753
EPS(LYR):-1.8300
ROE:-15.31%
ROA:-11.00%
PB:5.01
PE(LYR):-33.42

Loading ...

Enliven CMO Helen Louise Collins disposes of shares worth $239,842

Reuters
·
Apr 22

Enliven Therapeutics announces annual shareholder meeting

Reuters
·
Apr 16

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), Viridian Therapeutics (VRDN) and Soleno Therapeutics (SLNO)

TIPRANKS
·
Apr 11

U.S. RESEARCH ROUNDUP-Chevron, Littelfuse, Parker-Hannifin

Reuters
·
Apr 10

Leveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target

TIPRANKS
·
Apr 08

JonesTrading Keeps Their Buy Rating on Enliven Therapeutics (ELVN)

TIPRANKS
·
Apr 07

LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)

TIPRANKS
·
Mar 28

Enliven Therapeutics; Chief Medical Officer Helen Louise Collins disposes of 40,000 common shares valued at $1,404,024

Reuters
·
Mar 28

Enliven rises 11.0%

TIPRANKS
·
Mar 27

Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $56 From $48

THOMSON REUTERS
·
Mar 26

BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings

Reuters
·
Mar 26

BUZZ-Enliven gains after Jones raises PT on increased takeover appeal

Reuters
·
Mar 25

Enliven up 20% after Terns Pharmaceuticals agrees to be bought by Merck

TIPRANKS
·
Mar 25

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Reuters
·
Mar 25

Enliven Therapeutics CMO Helen Louise Collins disposes of USD 138,800 in common shares

Reuters
·
Mar 20

Enliven Therapeutics CMO Helen Louise Collins Disposes of Common Shares

Reuters
·
Mar 12

Enliven Therapeutics: Compelling Early ELVN-001 Data and De-Risked Development Path Support Buy Rating

TIPRANKS
·
Mar 06

Enliven Therapeutics: Compelling ELVN-001 CML Data, Strong Cash Runway Support Buy Rating

TIPRANKS
·
Mar 04

Enliven Therapeutics Q4 net loss widens on higher expenses

Reuters
·
Mar 04

Enliven posts FY 2025 net loss of USD 103.7 million and Q4 2025 G&A expenses of USD 13.0 million (+111.3%)

Reuters
·
Mar 04